CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-05-17 | Verwiel Frank Director | Grant or award · Stock Option (right to buy) | +19,000 | 19,000 | ||
| 2018-05-16 | FORMELA JEAN FRANCOIS Director | Sale | −6,686 | $25.04 | $167K | 0 |
| 2018-05-14 | LEONARD JOHN M. President and CEO | Sale | −8,400 | $24.00 | $202K | 0 |
| 2018-05-01 | SCHIERMEIER ANDREW EVP, Corporate Strategy | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2018-03-28 | Bell Graeme EVP, Chief Financial Officer | Option exercise | +8,000 | $13.48 | $108K | 21,400 |
| 2018-03-28 | Bell Graeme EVP, Chief Financial Officer | Option exercise · Stock Option (Right to buy) | −8,000 | 202,000 | ||
| 2018-03-23 | DORSA CAROLINE Director | Grant or award | +410 | $24.05 | $10K | 5,410 |
| 2018-03-20 | FORMELA JEAN FRANCOIS Director | Sale | −2,617 | $25.06 | $66K | 36,628 |
| 2018-03-20 | FORMELA JEAN FRANCOIS Director | Sale | −36,628 | $23.78 | $871K | 0 |
| 2018-01-29 | Caribou Biosciences, Inc. 10% owner | Sale | −550,645 | $26.78 | $14.7M | 3,994,355 |
| 2018-01-25 | LEONARD JOHN M. CEO | Grant or award · Stock Option (right to buy) | +220,000 | 220,000 | ||
| 2018-01-25 | Bell Graeme EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2018-01-25 | Rivera Jose E EVP, General Counsel | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-12-12 | Rivera Jose E EVP, General Counsel | Grant or award · Stock Option (right to buy) | +72,500 | 72,500 | ||
| 2017-12-12 | LEONARD JOHN M. EVP, R&D | Grant or award · Stock Option (right to buy) | +72,500 | 72,500 | ||
| 2017-12-12 | Bermingham Nessan President & CEO | Grant or award · Stock Option (right to buy) | +292,500 | 292,500 | ||
| 2017-12-12 | Bell Graeme EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +72,500 | 72,500 | ||
| 2017-12-12 | Novartis Institutes for BioMedical Research, Inc. 10% owner | Sale | −1,523,000 | $18.30 | $27.9M | 4,129,903 |
| 2017-12-08 | Bermingham Nessan President & CEO | Sale | −94,143 | $20.82 | $2.0M | 458,250 |
| 2017-12-07 | Bermingham Nessan President & CEO | Sale | −103,574 | $21.05 | $2.2M | 579,959 |
Page 35 of 40 · 783 trades